Select Publications
Journal articles
2018, 'Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer', JNCI: Cancer Spectrum, 2, pp. pky047, http://dx.doi.org/10.1093/jncics/pky047
,2018, 'Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN', Cancer Research, 78, pp. 3122 - 3134, http://dx.doi.org/10.1158/0008-5472.CAN-17-3034
,2018, 'Too many targets, not enough patients: Rethinking neuroblastoma clinical trials', Nature Reviews Cancer, 18, pp. 389 - 400, http://dx.doi.org/10.1038/s41568-018-0003-x
,2018, 'NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10558
,2018, 'MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, 1861, pp. 235 - 245, http://dx.doi.org/10.1016/j.bbagrm.2018.01.007
,2018, 'A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children', British Journal of Haematology, 180, pp. 550 - 562, http://dx.doi.org/10.1111/bjh.15056
,2018, 'PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia', ESMO Open, 3, pp. A238 - A238, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.563
,2017, 'High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment', Haematologica, 102, pp. e490 - e493, http://dx.doi.org/10.3324/haematol.2016.162925
,2017, 'Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo', European Journal of Cancer, 83, pp. 132 - 141, http://dx.doi.org/10.1016/j.ejca.2017.06.024
,2017, 'A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers', Cancer Research, 77, pp. 971 - 981, http://dx.doi.org/10.1158/0008-5472.CAN-15-2906
,2016, 'Polyamine antagonist therapies inhibit neuroblastoma initiation and progression', Clinical Cancer Research, 22, pp. 4391 - 4404, http://dx.doi.org/10.1158/1078-0432.CCR-15-2539
,2016, 'Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia', Leukemia, 30, pp. 1745 - 1748, http://dx.doi.org/10.1038/leu.2016.24
,2016, 'MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin', Cancer Research, http://dx.doi.org/10.1158/0008-5472.CAN-15-0879
,2016, 'Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis', Molecular Oncology, 10, pp. 866 - 878, http://dx.doi.org/10.1016/j.molonc.2016.02.004
,2016, 'ABC transporters as mediators of drug resistance and contributors to cancer cell biology', Drug Resistance Updates, 26, pp. 1 - 9, http://dx.doi.org/10.1016/j.drup.2016.03.001
,2016, 'High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients', Cancer Letters, 374, pp. 315 - 323, http://dx.doi.org/10.1016/j.canlet.2016.02.021
,2016, 'CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements', Oncotarget, 7, pp. 46067 - 46087, http://dx.doi.org/10.18632/oncotarget.10022
,2016, 'Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth', Oncotarget, 7, pp. 47479 - 47493, http://dx.doi.org/10.18632/oncotarget.10201
,2016, 'Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer', Oncotarget, 7, pp. 6353 - 6368, http://dx.doi.org/10.18632/oncotarget.7047
,2016, 'MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4', Oncotarget, 7, pp. 54937 - 54951, http://dx.doi.org/10.18632/oncotarget.10709
,2016, 'The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs', Oncotarget, 7, pp. 79217 - 79232, http://dx.doi.org/10.18632/oncotarget.12640
,2016, 'The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression', Oncotarget, 7, pp. 8663 - 8675, http://dx.doi.org/10.18632/oncotarget.6675
,2016, 'Predictors of success of phase 2 paediatric oncology clinical trials', European Journal of Cancer, 69, pp. S63 - S64, http://dx.doi.org/10.1016/s0959-8049(16)32778-2
,2016, 'Proffered Paper: Targeting PA2G4, a novel MYCN co-factor, for the treatment of neuroblastoma', European Journal of Cancer, 61, pp. S7 - S7, http://dx.doi.org/10.1016/s0959-8049(16)61016-x
,2015, 'Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma', Science Translational Medicine, 7, pp. 312ra176, http://dx.doi.org/10.1126/scitranslmed.aab1803
,2015, 'Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma', Molecular Oncology, 9, pp. 1484 - 1500, http://dx.doi.org/10.1016/j.molonc.2015.04.005
,2015, 'Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma', TRANSLATIONAL PEDIATRICS, 4, pp. 226 - 238, http://dx.doi.org/10.3978/j.issn.2224-4336.2015.04.06
,2015, 'Folate pathway gene polymorphisms and risk of childhood brain tumors: Results from an Australian case-control study', Cancer Epidemiology Biomarkers and Prevention, 24, pp. 931 - 937, http://dx.doi.org/10.1158/1055-9965.EPI-14-1248
,2015, 'Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia', British Journal of Haematology, 168, pp. 395 - 404, http://dx.doi.org/10.1111/bjh.13142
,2015, 'ABC Transporters and Neuroblastoma', , 125, pp. 139 - 170, http://dx.doi.org/10.1016/bs.acr.2014.10.005
,2015, 'Folate pathway gene polymorphisms, maternal folic acid use, and risk of childhood acute lymphoblastic leukemia', Cancer Epidemiology Biomarkers and Prevention, 24, pp. 48 - 56, http://dx.doi.org/10.1158/1055-9965.EPI-14-0680
,2015, 'MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma', Oncotarget, 6, pp. 15510 - 15523, http://dx.doi.org/10.18632/oncotarget.3732
,2014, 'GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis', Blood, 124, pp. 3284 - 3294, http://dx.doi.org/10.1182/blood-2013-10-532523
,2014, 'High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)', Biochemical Pharmacology, 91, pp. 97 - 108, http://dx.doi.org/10.1016/j.bcp.2014.05.023
,2014, 'ABCA transporter gene expression and poor outcome in epithelial ovarian cancer', Journal of the National Cancer Institute, 106, pp. dju149, http://dx.doi.org/10.1093/jnci/dju149
,2014, 'Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer', Scientific Reports, 4, pp. 4669, http://dx.doi.org/10.1038/srep04669
,2014, 'USE OF NOVEL PATIENT-DERIVED XENOGRAFTS AND MOLECULAR SUBTYPING TO IMPROVE PRECISION MEDICINE IN HIGH-GRADE SEROUS OVARIAN CANCER', EUROPEAN JOURNAL OF CANCER, 50, pp. E9 - E9, http://dx.doi.org/10.1016/j.ejca.2014.03.042
,2014, 'The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1', Oncotarget, 5, pp. 1793 - 1804, http://dx.doi.org/10.18632/oncotarget.1785
,2014, 'Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach', Journal of Proteomics, 96, pp. 1 - 12, http://dx.doi.org/10.1016/j.jprot.2013.10.032
,2014, 'An unexpected role for caspase-2 in neuroblastoma', Cell Death and Disease, 5, pp. e1383 - e1383, http://dx.doi.org/10.1038/cddis.2014.342
,2014, 'Histone Deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1', Oncotarget, 5, pp. 4257 - 4268, http://dx.doi.org/10.18632/oncotarget.1991
,2014, 'Molecular profiling of childhood cancer: Biomarkers and novel therapies', BBA Clinical, 1, pp. 59 - 77, http://dx.doi.org/10.1016/j.bbacli.2014.06.003
,2014, '421 Molecular profiling for factors predicting sensitivity or resistance to therapy in relapsed child cancer', European Journal of Cancer, 50, pp. 135, http://dx.doi.org/10.1016/s0959-8049(14)70547-7
,2014, 'Neuroblastoma: molecular targets and novel therapies', Pathology, 46, pp. S36 - S36, http://dx.doi.org/10.1097/01.pat.0000454208.74479.75
,2013, 'GPR84, a Proinflammatory Receptor, Sustains Wnt/β-Catenin Signaling In Leukemic Stem Cells For Maintenance Of MLL-AF9-Induced Leukemogenesis', Blood, 122, pp. 3781, http://dx.doi.org/10.1182/blood.v122.21.3781.3781
,2013, 'Improving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients with Earlier Quantification of Minimal Residual Disease', PLoS ONE, 8, pp. e76455, http://dx.doi.org/10.1371/journal.pone.0076455
,2013, 'High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation', Leukemia, 27, pp. 1497 - 1503, http://dx.doi.org/10.1038/leu.2013.44
,2013, 'B-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma', British Journal of Cancer, 108, pp. 2485 - 2494, http://dx.doi.org/10.1038/bjc.2013.205
,2013, 'ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and the Cancer Genome Atlas', Gynecologic Oncology, 131, pp. 8 - 14, http://dx.doi.org/10.1016/j.ygyno.2013.07.107
,2013, 'Cell-based methods for the identification of Myc-inhibitory small molecules', Methods in Molecular Biology, 1012, pp. 255 - 264, http://dx.doi.org/10.1007/978-1-62703-429-6_18
,